CFP and age-related macular degeneration: In the meanwhile clinical studies already indicate a potent impact of anti-Properdin antibodies in AMD patients: Intravitreal injection of 10 mg anti-Properdin antibodies reduced the lesion size in GA patients by ~16% compared to sham treated patients in phase 2 studies (not yet significant, NCT02515942).